Stockreport

Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007

FIBROCELL SCIENCE INC COMMON  (FCSC) 
NASDAQ:AMEX Investor Relations: fibrocell.com
PDF Company Plans to Submit Phase 3 Protocol to FDA in Fourth Quarter of 2018 and Commence Trial in First Half of 2019  EXTON, Pa., Oct. 25, 2018 (GLOBE NEWSWIRE) -- [Read more]